These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9849446)

  • 1. Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial.
    Decensi A; Torrisi R; Fontana V; Barreca A; Ponzani P; Pensa F; Parodi S; Costa A
    Eur J Cancer; 1998 Jun; 34(7):999-1003. PubMed ID: 9849446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
    Herbert BS; Sanders BG; Kline K
    Nutr Cancer; 1999; 34(2):121-32. PubMed ID: 10578478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
    Decensi A; Formelli F; Torrisi R; Costa A
    J Cell Biochem Suppl; 1993; 17G():226-33. PubMed ID: 8007703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
    Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
    Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
    Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN
    Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of breast cancer with fenretinide.
    Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
    Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer chemoprevention.
    Costa A
    Eur J Cancer; 1993; 29A(4):589-92. PubMed ID: 8382073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
    Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
    Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic retinoid fenretinide in breast cancer chemoprevention.
    Bonanni B; Lazzeroni M; Veronesi U
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.
    Kong FM; Anscher MS; Murase T; Abbott BD; Iglehart JD; Jirtle RL
    Ann Surg; 1995 Aug; 222(2):155-62. PubMed ID: 7543740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell death induced by N-(4-hydroxyphenyl)retinamide in human epidermal keratinocytes is modulated by TGF-beta and diminishes during the progression of squamous cell carcinoma.
    Davies M; Paterson IC; Ganapathy A; Prime SS
    Int J Cancer; 2006 Dec; 119(12):2803-11. PubMed ID: 17044020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
    Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
    J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
    J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.
    Torrisi R; Parodi S; Fontana V; Pensa F; Casella C; Barreca A; De Palo G; Costa A; Decensi A
    Int J Cancer; 1998 Jun; 76(6):787-90. PubMed ID: 9626341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
    Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
    Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.